Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff sold 18,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the completion of the sale, the chief executive officer owned 136,583 shares in the company, valued at approximately $3,700,033.47. This represents a 12.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Agios Pharmaceuticals Trading Down 0.1%

NASDAQ AGIO traded down $0.04 during trading hours on Friday, reaching $27.18. 891,433 shares of the company’s stock were exchanged, compared to its average volume of 1,512,286. The stock has a market cap of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. The firm has a fifty day moving average of $32.20 and a 200-day moving average of $35.96. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. Agios Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter last year, the business posted $16.22 earnings per share. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. Wellington Management Group LLP lifted its position in Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. TCG Crossover Management LLC increased its stake in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares during the period. SCS Capital Management LLC acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $17,905,000. Balyasny Asset Management L.P. bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $19,889,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Agios Pharmaceuticals by 145.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock valued at $21,770,000 after purchasing an additional 440,000 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AGIO. Bank of America raised their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $57.00 to $28.00 in a research report on Wednesday, November 19th. Leerink Partnrs upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 20th. JPMorgan Chase & Co. decreased their price objective on Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, November 21st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.89.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.